Cargando…

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

BACKGROUND: Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsujikawa, Laura M., Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D., Stotz, Stephanie C., Sarsons, Christopher D., Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626370/ https://www.ncbi.nlm.nih.gov/pubmed/31300040 http://dx.doi.org/10.1186/s13148-019-0696-z

Ejemplares similares

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
por: Gilham, Dean, et al.
Publicado: (2023)

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
por: Fu, Li, et al.
Publicado: (2023)

Benefit of Apabetalone on Plasma Proteins in Renal Disease
por: Wasiak, Sylwia, et al.
Publicado: (2017)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

RVX 208
Publicado: (2012)

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
por: Fu, Li, et al.
Publicado: (2022)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
por: Lu, Panpan, et al.
Publicado: (2017)

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Ning, Dong, et al.
Publicado: (2020)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Reply to Ning et al.: More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Provencher, Steeve, et al.
Publicado: (2020)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021)

ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin‐1‐dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone
por: Aguirre‐Portolés, Cristina, et al.
Publicado: (2018)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Understanding and improving assays for cytotoxicity of nanoparticles: what really matters?
por: Labouta, Hagar I., et al.
Publicado: (2018)

Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition
por: Lin, Xionghao, et al.
Publicado: (2019)

Small Molecules Targeted to a Non-Catalytic “RVxF” Binding Site of Protein Phosphatase-1 Inhibit HIV-1
por: Ammosova, Tatiana, et al.
Publicado: (2012)

Place your bets: psychophysiological correlates of decision-making under risk
por: Studer, Bettina, et al.
Publicado: (2011)

Directed Flow in 158 A GeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1998)

Freeze-Out Parameters in Central 158 AGeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1999)

Surface-grafted polyethylene glycol conformation impacts the transport of PEG-functionalized liposomes through a tumour extracellular matrix model
por: Labouta, Hagar I., et al.
Publicado: (2018)

Measurement of conversion electrons with the $^{208}Pb(p,n)^{208}Bi$ reaction and derivation of the shell model proton neutron hole interaction from the properties of $^{208}Bi$
por: Maier, K H, et al.
Publicado: (2007)

Direct Photon Production in 158 A GeV $^{208}Pb+^{208}Pb$ collisions
por: Aggarwal, M.M., et al.
Publicado: (2001)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Competition between Allowed and First-Forbidden $β$ Decay: The Case of $^{208}$Hg$→^{208}$Tl
por: Carroll, R J, et al.
Publicado: (2020)

Observation of Direct Photons in Central 158 A GeV $^{208}Pb+^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (2000)

Interferometry of direct photons in central $^{208}$Pb+$^{208}$Pb collisions at 158A GeV
por: Aggarwal, M M, et al.
Publicado: (2004)

$\Delta^{++}$ production in 158 A GeV $^{208}Pb+^{208}Pb$ interactions at the CERN SPS
por: Aggarwal, M M, et al.
Publicado: (2000)

Cantata no. 208 Was mir behagt : Hunt cantata /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1986)

Competition between allowed and first-forbidden $β$ decays of $^{208}$At and expansion of the $^{208}$Po level scheme
por: Brunet, M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hs3ru2nssusko5ao266ecoq75e